CRISPR could help doctors attack blood cancer without destroying healthy cells

Researchers used CRISPR to remove CD33 from donor stem cells, potentially offering a way to attack aggressive blood cancers while protecting healthy cells needed after transplant. In a reported 30-patient trial, the edited cells successfully took hold and appeared to shield blood cells from a CD33-targeted treatment; this remains an early-stage trial result.

Headlines are indexed or machine translated, not independent verification of scientific results. Medical news is not clinical advice. Distinguish interstellar concepts from demonstrated space technology using the original source.